**BEZLOTOXUMAB**

<table>
<thead>
<tr>
<th>BRAND NAME</th>
<th>ZINPLAVA</th>
</tr>
</thead>
<tbody>
<tr>
<td>DRUG CLASS</td>
<td>Monoclonal antibody (human) for <em>C. difficile</em> infection</td>
</tr>
<tr>
<td>AVAILABILITY</td>
<td>Vial contains 1 g/40 mL of bezlotoxumab. Also contains sodium chloride, sodium citrate dihydrate, citric acid monohydrate, polysorbate-80, pentectic acid. The solution is clear to opalescent and colourless to pale yellow.</td>
</tr>
</tbody>
</table>

**WARNING**

The occupational hazard of intermittent low dose exposure to bezlotoxumab is not known. Wear a mask and gloves when preparing the infusion solution to minimise exposure.

**pH**

6

**PREPARATION**

Dilute before use. **Do not shake.**

**STABILITY**

Vial: store at 2 to 8 °C. Protect from light. Stable at 25 °C for up to 24 hours prior to preparation of the infusion solution. Infusion solution: stable for 16 hours 25 °C or for 24 hours at 2 to 8 °C.

**ADMINISTRATION**

- **IM injection**: Not recommended
- **SUBCUT injection**: Not recommended
- **IV injection**: Not recommended
- **IV infusion**: Dilute to a final concentration of 1–10 mg/mL with a compatible fluid. For most patients 100 mL is a suitable volume. Mix by gently inverting the bag. **Do not shake.** Infuse over 60 minutes. Use a low-protein binding 0.2–5 micron filter.

**COMPATIBILITY**

- **Fluids**: Glucose 5%, sodium chloride 0.9%
- **Y-site**: No information

**INCOMPATIBILITY**

- **Fluids**: No information
- **Drugs**: No information

**SPECIAL NOTES**

Infusion reactions including nausea, fatigue, dizziness, headache, dyspnoea and hypertension may occur on the day of or the day after the infusion.

**REFERENCES**